Bioluminescent Bacterial Imaging In Vivo
November 4th, 2012
This article describes the administration of lux-tagged bacteria to mice and subsequent in vivo analysis using IVIS bioluminescence imaging.
This video describes the use of whole body bioluminescent imaging for the study of bacterial trafficking in live mice, with an emphasis on detection of bacterial growth within tumor xenografts bacteria present an attractive class of vector for cancer therapy, possessing a natural ability to grow preferentially within tumors, following intravenous administration growing either external to or within tumor cells. Bacterial strains engineered to express the lux gene cassette facilitate detection of the bacteria and concurrently tumors. The value of non-invasive longitudinal monitoring of bacterial strains in vivo is well accepted, reducing animal usage and generating more statistically relevant data than endpoint assays.
This procedure involves the induction of subcutaneous tumors in mice. Tumors are permitted to develop and monitored over time. Bacteria are Administered and mice are subjected to bioluminescence imaging at dedicated time points For the Experiments described here.
Subcutaneous tumors are induced in mice of either an immune competent or a thymic background. Depending on choice of xenograft, Lux type bacteria of the desired species such as e coli, Are grown as overnight cultures. Bacterial cells are washed and resuspended at the desired concentration for intravenous administration.
10 to the six. Bacterial cells in an injection volume of 100 microliters is routinely used. Mice bearing subcutaneous tumors routinely 100 millimeters Cuban volume are prepared for treatment.
Using a 29 gauge syringe needle, the bacterial suspension is injected to the lateral tail vein. The bacteria Preferentially replicated within the tumor mass over time. Intratumoral bacteria continue to replicate for several weeks and are detectable by IVUS Imaging between three and six days.
Post administration For bioluminescent imaging live and anesthetized mice are placed within the 37 degree chamber of the ivus. If desired, several mice can be imaged Simultaneously. Photographic and luminescent light images are collected using a cooled CCD camera at the desired software settings.
Depending on the imaging device, two or three dimensional analysis may be performed. A robust And linear relationship between intratumoral bacterial numbers and the levels of light produced is achieved permitting. Reliable estimation of bacterial Numbers in vivo LX expressing bacteria May also be detected from deep within the body.
Lux expressing gut colonizing commensal bacteria are visualized for several weeks. Post cavage administration further demonstrating the utility of bioluminescent imaging for the analysis of lux expressing bacteria within research animals.
View the full transcript and gain access to thousands of scientific videos
Overview
This article describes the use of whole body bioluminescent imaging to study bacterial trafficking in live mice. The focus is on detecting bacterial growth within tumor xenografts, highlighting the potential of bacteria as vectors for cancer therapy.
Key Study Components
Area of Science
- Neuroscience
- Biology
- Cancer therapy
Background
- Bacteria can preferentially grow within tumors, making them attractive for cancer treatment.
- Engineered bacterial strains expressing the lux gene allow for non-invasive monitoring.
- Longitudinal imaging reduces animal usage and provides statistically relevant data.
- Subcutaneous tumors are induced in mice for the study.
Purpose of Study
- To analyze bacterial trafficking in live mice using bioluminescence imaging.
- To monitor bacterial growth within tumor xenografts over time.
- To demonstrate the utility of bacteria as therapeutic vectors.
Methods Used
- Induction of subcutaneous tumors in mice.
- Administration of lux-tagged bacteria.
- Bioluminescence imaging at dedicated time points.
- Longitudinal monitoring of bacterial strains in vivo.
Main Results
- Successful detection of bacterial growth within tumors.
- Demonstrated non-invasive imaging technique for tracking bacteria.
- Provided insights into bacterial behavior in tumor environments.
- Validated the use of engineered bacteria for cancer therapy.
Conclusions
- Bacteria can serve as effective vectors for cancer treatment.
- Bioluminescence imaging is a valuable tool for in vivo studies.
- The study supports the potential of bacteria in therapeutic applications.
Frequently Asked Questions
Executive Industry Relevance
Bioluminescent bacterial imaging enables real-time, non-invasive tracking of bacterial trafficking in vivo, supporting preclinical evaluation of bacterial vectors for cancer therapy. This approach reduces animal usage while providing longitudinal, quantitative data on tumor targeting and bacterial persistence. The method enhances predictive confidence in early-stage therapeutic vector development by visualizing spatial and temporal dynamics of bacterial localization within tumors.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of bacterial tumor tropism and preferential growth within xenograft models.
- Operational Value: Supports functional validation of engineered bacterial strains as therapeutic vectors through longitudinal monitoring.
- Predictive Value: Facilitates mechanistic de-risking by correlating bacterial signal intensity with intratumoral burden over time.
Screening & Assay Development
- Scientific Value: Provides a standardized, quantitative readout for assessing bacterial delivery and replication in tumor tissues.
- Operational Value: Enables high-throughput, non-terminal imaging workflows compatible with IVIS-based platforms.
- Assay Readiness: Generates linear signal-to-bacterial-number relationships for reliable in vivo quantification.
Translational & Preclinical Research
- Scientific Value: Demonstrates utility across bacterial species and tumor xenograft types, supporting broad applicability in oncology.
- Operational Value: Allows visualization of commensal bacteria in the gastrointestinal tract post-administration, expanding utility to microbiome studies.
- Translational Continuity: Supports risk-adjusted advancement decisions by tracking bacterial persistence and tumor localization over several weeks.
Pipeline & Workflow Integration
The method integrates into the discovery continuum from early vector screening through preclinical validation, enabling iterative design-build-test cycles for bacterial therapeutics.
- Discovery Biology: Supports hypothesis testing of bacterial tumor targeting mechanisms via spatial and temporal imaging readouts.
- Screening: Delivers reproducible, quantitative bioluminescent outputs for comparing bacterial strains or dosing regimens.
- Analytics: Generates linear luminescence-bacterial count correlations enabling statistical comparison of experimental conditions.
- Translational Research: Connects early vector characterization to preclinical validation through longitudinal tumor monitoring.
- Enterprise Reuse: Establishes a reusable imaging platform for evaluating diverse bacterial vectors across oncology and infectious disease programs.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity in bacterial-vector behavior through real-time, in vivo tracking.
- Operational Value: Standardizes longitudinal monitoring, reducing variability and animal cohort sizes.
- Strategic Value: Improves go/no-go decisions by providing early, predictive data on vector tumor localization and persistence.
- Portfolio Impact: Enables risk-adjusted prioritization of bacterial therapeutic candidates based on quantitative trafficking data.
Implementation Considerations
- Requires expertise in bacterial culture, lux-tagging, and intravenous administration in murine models.
- Dependent on IVIS or comparable bioluminescence imaging systems with cooled CCD cameras and environmental chambers.
- Necessitates standardization of bacterial preparation, injection volume, and imaging time points across studies.
- Adaptation considerations include bacterial species selection, tumor model compatibility, and substrate (luciferin) delivery methods.
- Practical limitations include signal attenuation in deep tissues and potential interference from endogenous luminescence or gut flora.
